11:33 AM EDT, 07/15/2025 (MT Newswires) -- Guardant Health ( GH ) said Tuesday it enrolled the first patient in the National Cancer Institute's Vanguard Study to evaluate its Shield multi-cancer detection technology.

The technology was selected for use in a four-year study that plans to enroll up to 24,000 participants.

The Shield MCD test was recently granted breakthrough device designation by the US Food and Drug Administration for screening a range of cancers in individuals aged 45 or older, the company said.

Price: 49.44, Change: -0.33, Percent Change: -0.66